Simon JA
No ORCID on file
· 19 papers in corpus
· active 1991-2025
Study types
- article 5
- review 5
- other 2
- rct 2
- letter 1
Condition tags
- endometriosis 14
- adenomyosis 5
- chronic_pelvic_pain 4
- dysmenorrhea 3
- dyspareunia 2
- infertility 1
Top journals
Frequent coauthors
- James A. Simon 14
- Thomas Jw 5
- Archer Df 5
- Carr BR 5
- Watts Nb 5
- Lauren D. Arnold 4
- Arnold LL 4
- Joseph Ng 4
- Duan WR 4
- James W. Thomas 4
article
2025
BACKGROUND: Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss of bone mi…
rct
2024
BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…
2024
ObjectiveTo investigate the efficacy of elagolix plus add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily) on patient-reported nonbleeding symptoms and menstrual bleeding associated with uterine fibroids (UFs) a…
review
2021
Bone mineral density (BMD) changes during the life span, increasing rapidly during adolescence, plateauing in the third decade of life, and subsequently entering a phase of age-related decline. In women, menopause leads to accelerated bone …
2020
ObjectiveTo investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas.Met…
2019
ObjectiveTo evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women.MethodsWomen who completed the 24-week double-blind core phase of RECONNECT, composed of two p…
2018
ObjectiveTo evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyoma…
article
2018
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…
article
2018
We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the c…
rct
2017
BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…
review
2011
New therapies for abnormal uterine bleeding have been slow to reach the marketplace for a variety of reasons. These reasons include the availability of cost-effective therapies already available and the extraordinarily difficult and expensi…
review
2006
ObjectiveTo comprehensively review and evaluate the direct costs of endometriosis.Design and settingWe systematically reviewed studies published since 1990, and conducted an analysis of publicly available national databases (Healthcare Cost…
article
2004
ObjectiveThe purpose of this study was to assess the in vitro effect of gonadotropin-releasing hormone agonist on natural killer cell activity in women with and without endometriosis and to ascertain whether gonadotropin-releasing hormone a…
other
2001
OBJECTIVE: A possible association of endometriosis with decreased bone mineral density in women has been proposed. It has been reported that cortical and trabecular bone mass of the distal portion of the radius is decreased in patients with…
letter
1995
review
1995
OBJECTIVE: To survey the nonsurgical diagnostic techniques for distinguishing adenomyosis, and to determine whether one technique offers diagnostic advantages. DATA SOURCES: We conducted a thorough search of the MEDLINE data base and identi…
other
1994
PURPOSE: To prospectively compare conventional spin-echo magnetic resonance (MR) imaging and transvaginal sonography for the diagnosis of adenomyosis. MATERIALS AND METHODS: Twenty women with clinically suspected adenomyosis underwent MR i…
article
1994
The persuasive data not only illustrate a familial tendency towards adenomyosis but also emphasize that adenomyosis can be diagnosed noninvasively and accurately by MRI. A possible familial predisposition toward or a direct familial cause o…
review
1991
Intrauterine insemination is commonly performed in the treatment of infertility. Infectious complications associated with intrauterine insemination are frequently cited, though rarely reported. A review of the literature yields only five re…